Abuse or misuse of caffeine has been implicated in the pathogenesis of a variety of clinical disorders and measurement of its plasma concentration is likely to become important in clinical laboratories in the future. A rapid, sensitive and easily performed method for the measurement of caffeine in biological fluids by the technique of fluoroimmunoassay is described. The results produced are precise and agree well with those obtained by radioimmunoassay or HPLC. Cross-reactivity of the antiserum with other substituted xanthines and uric acids is negligible for the major metabolites of caffeine but there is significant cross-reactivity with theophylline at concentrations likely to be found when this drug is being administered therapeutically. The measurement of caffeine by fluoroimmunoassay has a place in the clinical laboratory particularly where small batches of samples are to be analysed.
More people are exposed to caffeine in their everyday lives than to probably any other drug, due to its presence in drinks and food made or flavoured with coffee, tea or chocolate. In addition, it is present in cola drinks and some non-prescription analgesics. Various studies have suggested a possible role for caffeine or, at least, caffeinated beverages in the development of heart disease, 1 peptic ulcer.? cancers of the urinary tract': 4 and, most recently, cancer of the pancreas'': 6, 7 although none of these associations have withstood critical examination. Excessive caffeine intake is, however, associated with the syndrome of 'caffeinism' which can be confused with anxiety neurosis and is characterised by symptoms of nervousness, irritability, agitation, headache and tremulousness . 8, 9 Physical dependence on caffeine is common and manifests itself as headache following acute caffeine withdrawal which can readily be reversed by the administration of caffeine.f III The amount of caffeine in a cup of caffeinated beverage depends on the type of beverage, its mode of preparation and the size of the cup.l! Surveys relying on subjective assessments of consumption are affected by reticence and inaccuracy and studies using this approach to assess caffeine status are unreliable. A better index of exposure to caffeine is given by measurement of plasma caffeine levels, and a reference range derived from a study of 600 random out-patients has recently been reported. 12 Caffeine in blood and plasma has been measured by spectrophotometry, 13 gas-liquid chromatography (GLC),14 high-performance liquid chromatography (HPLC)15 and radioimmunoassay (RIA). 16 The spectrophotometric method involving the use of benzene, a carcinogenic solvent, requires large volumes of sample and is both imprecise and inaccurate because of interference by endogenous and other compounds. The other three methods, i.e. GLC, HPLC and RIA, involve the use of expensive, sophisticated instrumentation and are not well suited to rapid analysis. Fluoroimmunoassay is a recently established, sensitive and specific technique for measuring the concentration of drugs in blood.
In this study the measurement of caffeine in the blood by a substrate-labelled fluoroimmunoassay technique is evaluated and compared with the radioimmunoassay method routinely employed in this laboratory.
Materials and methods
All chemicals used were Analar grade and were supplied by BDH Chemicals, Poole, England unless otherwise stated. The Ames" Fluoro-stat and Ames" diluter, together with the antibody--enzyme reagent, tluorogenic caffeine reagent and tluoroimmunoassay (bicine) buffer were kindly donated by Dr John Burd. Theophylline and theobromine were supplied by Sigma (London) Ltd, Poole, England.
Aqueous stock solutions of l-rnethylxanthine, 3-methylxanthine, 7-methylxanthine, 1,7-dimethylxanthine, I-methyluric acid, 7methyluric acid, 1,3-dimethyluric acid, 1,7dimethyluric acid and 1,3,7-trimethyluric acid were kindly donated by Mr N Scott.
Fluorimetry cuvettes for use with the Ames tluorostat were supplied by Sarstedt, Leicester, England. (S-3H)-Caffeine tracer, used in the radioimmunoassay, was supplied by Amersham International pic, Amersham, Bucks., England. The caffeine antiserum used in the radioimmunoassay was a gift from Dr CE Cook. Donkey anti-rabbit serum was supplied by Guildhay Antisera, University of Surrey, Guildford, England.
Phosphate-buffered physiological saline (0,05 M, 150 mmol/l), pH 7·4, containing O·I%.w/v gelatin was prepared and used as diluent. Caffeine-free serum was prepared by treating pooled serum with agarose-coated charcoal. Caffeine standard solutions were prepared by diluting a 1 g/I (5,15 mrnol/l) stock solution of caffeine in phosphate buffer. Caffeine standards in a serum base were prepared by diluting the same stock solution in caffeine-free serum. Working standards in each case contained caffeine 0·5, 1·0, 2·5, 5·0, 10·0 and 15·0 mg/I (2·57, 5·15, 7·65, 25·7, 51·5, 77-3 umol/l), Theophylline and theobromine solutions were prepared in each case by diluting a 100 g/I stock solution in 1 M NaOH, with phosphate buffer, to give standards containing 1, 10, 100, 1000 and 10 000 mg/1.
Uric acid solutions were prepared by diluting a 2 g/I stock solution in 1 M NaOH, with phosphate buffer, to give standards containing 1, 10, 100, 1000 and 2000 mg/1. Stock solutions containing 200 mg/I of l-methylxanthine , 3methylxanthine, 1,7-dimethylxanthine, I-methyluric acid and 1,3,7-trimethyluric acid were diluted in phosphate buffer to give solutions containing 1, 10, 50, 100 and 200 mgll.
Heparinised plasma samples collected from ambulant out-patients were stored frozen. Prior to assay the samples were thawed and centrifuged to remove any particulate matter. It has been shown by radioimmunoassay that plasma and serum caffeine levels do not differ significantly.
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Principle
Caffeine added to the assay system competes with caffeine labelled with a tluorogenic substrate (umbelliferyl-js-n-galactoside) for a limited number of binding sites on an antibody raised against caffeine. Antibody-bound substrate is not available for hydrolysis by~ galactosidase which is, however, able to act on the free substrate with release of a tluorescent product. The measured tluorescence is proportional to the amount of added caffeine.
Procedure
A preliminary dilution of all working standard and plasma samples was made by diluting 50 111 with 2500 111 bicine buffer. All dilutions and standards were made with the Ames dilutor and assayed in duplicate. Fluorimetry cuvettes were placed in a heating block in a water bath set at 30°C, and 50 111 antibody--enzyme reagent, diluted with 500 111 bicine buffer pre-warmed to 30°C, was transferred to each cuvette. Fifty microlitres of each diluted sample or standard was diluted with 500 111 pre-warmed bicine buffer and transferred to the appropriate cuvette. Then 50 111 of the tluorogenic caffeine reagent, diluted with 500 111 of pre-warmed bicine buffer was added with force, to ensure adequate mixing, to each cuvette at IS-second intervals. Each cuvette was incubated for 20 minutes exactly and the resultant tluorescence measured on the Fluorostat fitted with a 405 nm excitation, and a 450 nm emission filter.
The Ames Fluorostat, a microprocessorcontrolled instrument, is programmed so that the standard and samples are usually presented to it in the following order: (1) each standard in duplicate, in descending order of concentration and (2) each sample in duplicate. This procedure was followed in the present protocol.
RADIOIMMUNOASSAY
The RIA used was based on that reported by Cook et al. 16 Separation of free and bound caffeine was effected by means of second antibody diluted in 12·5% polyethylene glycol.
Results
Using the method described, accurate and reproducible measurements of caffeine in plasma could be made simply and quickly. A comparison of results obtained by tluoroimmunoassay on samples from 45 out-patients with 30 The detection limit of the assay was calculated using the definition given by Ekins,17 namely
The zero standard was assayed nine times in a single batch and the error in measurement of 12 those obtained using the radioimmunoassay method in routine use in our laboratory is shown in Fig. 1 . Attempts to reduce incubation time were unsuccessful. Results obtained using a lO-minute incubation period were significantly lower (0·05> P> 0,025) than those obtained using 20-minute incubation.
The capacity of Fluorostat to store standard curves for use in subsequent caffeine assays was investigated. It was found, contrary to our previous experience with theophylline and phenytoin assays, that results calculated from stored curves were significantly different (0,025> P> 0,01) from those calculated from newly prepared standard curves. A standard curve was therefore prepared for each batch throughout this study. A mean standard curve is shown in Fig. 2 .
Antibody specificity was investigated by performing cross-reactivity studies with standard solutions of caffeine, substituted xanthines and uric acids, made up in 0·05 M phosphatebuffered saline. The results are shown in Table  1 . The percentage cross-reactivity was that measured when each of the compounds was present at a concentration equivalent to 200 mg/l in the original sample.
Caffeine was added to caffeine-free serum to give a final concentration of 2·5 mg/I (12,88 umol/l), Aliquots were assayed nine times in one batch. The mean recovery was 101±2·6% with a range of 96·8-105·7%. Fluoroimmunoassay of plasma caffeine 211 caffeine assay can be introduced into the clinical laboratory where scintillation counting facilities and sophisticated HPLC or GLC systems may not be readily available. Although therapeutic levels of caffeine and theophylline can nowadays be measured by relatively simple techniques they generally have inadequate sensitivity to measure the low concentrations normally encountered in ambulatory subjects not receiving specific therapy with methyl xanthines. A further advantage of the SLIFA technique over RIA and the chromatographic methods is that neither potentially hazardous radioactive materials nor organic solvents are used. The reagents used in the fluoroimmunoassay are stable under refrigerated conditions and minimal reagent and sample preparation is necessary prior to assay. There are no separation steps in the procedure and we have found that a batch of 15 samples can be processed by flu~r~immunoassay in a shorter time than by radioimmunoassay. However, the technique is not suitable for large batches of samples because of the necessity for accurately-timed incubations.
Our findings show the specificity of the antiserum to be acceptable for the measurement of caffeine in human plasma ( Table 1 ). The only compound which showed significant cross-reactivity was theophylline, which is only a minor metabolite of caffeine in man IX and should not normally affect the measured caffeine concentration. However, where theophylline is being administered therapeutically, plasma levels are likely to be high enough to cause significant interference. In neonates, theophylline is metabolised to caffeine in significant amounts." In man, the initial step in the metabolism of caffeine is thought to be demethylation at the 3-position to form 1,7dimethylxanthine.j" We have found a low cross-reactivity figure for this compound. Similarly, neither of the two major urinary metabolites of caffeine, l-rnethyluric acid and l-methylxanthine , showed significant crossreactivity with the antiserum. Although 1,3,7trimethyluric acid, which is structurally similar to caffeine, has a cross-reactivity figure of 2,5%, it is not thought to be a major metabolite of caffeine in man. 21 The recovery of caffeine added to caffeinefree serum was good and the detection limit of the assay was the same as that of our radioimmunoassay. The linearity study was performed using dilutions of a plasma sample from a patient with a high plasma caffeine concentra- response was taken as 2 standard deviations about the mean of the fluorescence readings. The calculated value for the detection limit of caffeine in plasma according to the criteria was 0·11 mg/I (0,56 umol/l) and the lowest concentration which could be measured accurately was taken to be 0·2 mg/I (1·03 umol/l), Linearity of the response to increasing amounts of caffeine was investigated by taking a plasma sample with a high caffeine concentration and making a series of dilutions in caffeinefree serum. The caffeine concentration of these preparations was determined experimentally and the results are shown in Fig. 3 .
Within-batch variation was determined by assaying the same sample nine times in a single assay. The mean value was 2·53 mg/I (13,0 urnol/l) with a coefficient of variation of 2·6%. Between-batch variation was studied at two levels of caffeine concentration. Each of two samples was measured once (in duplicate) in each of seven assays. The mean, standard deviation and coefficient of variation of the accumulated values for each sample was calculated. The sample with the lowest caffeine concentration contained 1·75 mg/I±SD 0·12: CV 6·9% (9·02±SD 0·60 umol), that with the high concentration 3·02 mg/I±SD 0·11: CV 3·5% (15·6±SD 0·56 umol/l).
tion. This ensured that caffeine metabolites were present throughout the range studied. The results show a slight discrepancy between the two highest caffeine concentrations and the lower values. This feature might not have been observed if the linearity study had been performed using a blank serum 'spiked' with caffeine, since such preparations do not contain caffeine metabolites.
We were impressed with the precision values it was possible to achieve with this system. Both within-and between-batch figures compared favourably with those generally obtained for radioimmunoassay techniques (5-10%). Accuracy of the method, as assessed by comparison of results with those obtained by our radioimmunoassay method was satisfactory. We have previously compared our radioimmunoassay results (RIA) with those obtained by Mr N Scott using an HPLC method for caffeine measurement (caffeine HPLC=0·998 caffeine RIA+0·128: r=0·9756). This suggests that the three techniques are comparable in terms of accuracy.
The relationship of plasma caffeine levels to the development of the pathological conditions with which caffeine ingestion has been implicated needs to be elucidated. This fluoroimmuno assay system is a welcome addition to the range of methods by which caffeine in biological fluids can be measured.
